1.
G Ital Dermatol Venereol
; 148(5): 546-7, 2013 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24005153
Assuntos
Escabiose/diagnóstico , Dermatoses do Couro Cabeludo/diagnóstico , Acaricidas/uso terapêutico , Criança , Feminino , Humanos , Permetrina/uso terapêutico , Escabiose/tratamento farmacológico , Dermatoses do Couro Cabeludo/tratamento farmacológico , Dermatoses do Couro Cabeludo/parasitologia
2.
J Dermatolog Treat
; 29(6): 583-585, 2018 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29334270
RESUMO
Psoriasis is a multi-systemic chronic inflammatory disease that affects about 1.5-3% of the general population, of which almost 20% suffer from a moderate-severe form. Those patients can be treated with a systemic agent and in case of scarce response or contraindications, they may require a biologic therapy, such as tumor necrosis factor or interleukin-12/23 inhibitors. When also these agents fail, clinicians face a true therapeutic challenge. We report a case series of multi-failure 16 patients, successfully treated with secukinumab, a human monoclonal antibody that selectively neutralizes interleukin-17 A and is recently approved for the treatment of plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.